Novartis’ Xolair (omalizumab) Receives EU’s Approval for Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU)

 Novartis’ Xolair (omalizumab) Receives EU’s Approval for Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU)

Novartis’ Xolair (omalizumab) Receives EU’s Approval for Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU)

Shots:
  • The approval is based on trial results assessing Xolair IV (q2w or q4w) in 1M patients with SAA and CSU for 13 years
  • The study demonstrated in reduction of severe exacerbations, corticosteroid use in SAA patients and reduction in symptoms of CSU with safe and well-tolerated results
  • Xolair (omalizumab) is a prefilled syringe (PFS) self-administered syringe, used for targeting  IgE and is approved by EU and the US FSA for moderate-to-severe or severe persistent allergic asthma in 2005 & 2003 respectively

Click here to read full press release/ article | Ref: Novartis | Image: Novartis

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post